Targeting protein arginine methyltransferase 5 sensitizes glioblastoma to trametinib.

MLA

Banasavadi-Siddegowda, Yeshavanth Kumar, et al. “Targeting Protein Arginine Methyltransferase 5 Sensitizes Glioblastoma to Trametinib.” Neuro-Oncology Advances, vol. 4, no. 1, June 2022, p. vdac095. EBSCOhost, https://doi.org/10.1093/noajnl/vdac095.

APA

Banasavadi-Siddegowda, Y. K., Namagiri, S., Otani, Y., Sur, H., Rivas, S., Bryant, J.-P., Shellbourn, A., Rock, M., Chowdhury, A., Lewis, C. T., Shimizu, T., Walbridge, S., Kumarasamy, S., Shah, A. H., Lee, T. J., Maric, D., Yan, Y., Yoo, J. Y., Kumbar, S. G., … Kaur, B. (2022). Targeting protein arginine methyltransferase 5 sensitizes glioblastoma to trametinib. Neuro-Oncology Advances, 4(1), vdac095. https://doi.org/10.1093/noajnl/vdac095

Chicago

Banasavadi-Siddegowda, Yeshavanth Kumar, Sriya Namagiri, Yoshihiro Otani, Hannah Sur, Sarah Rivas, Jean-Paul Bryant, Allison Shellbourn, et al. 2022. “Targeting Protein Arginine Methyltransferase 5 Sensitizes Glioblastoma to Trametinib.” Neuro-Oncology Advances 4 (1): vdac095. doi:10.1093/noajnl/vdac095.